WO2004012677A3 - Methods and compositions to treat conditions associated with neovascularization - Google Patents

Methods and compositions to treat conditions associated with neovascularization Download PDF

Info

Publication number
WO2004012677A3
WO2004012677A3 PCT/US2003/024455 US0324455W WO2004012677A3 WO 2004012677 A3 WO2004012677 A3 WO 2004012677A3 US 0324455 W US0324455 W US 0324455W WO 2004012677 A3 WO2004012677 A3 WO 2004012677A3
Authority
WO
WIPO (PCT)
Prior art keywords
neovascularization
compositions
methods
conditions associated
treat conditions
Prior art date
Application number
PCT/US2003/024455
Other languages
French (fr)
Other versions
WO2004012677A2 (en
Inventor
Kin-Ping Wong
Ming-Chung Wong
Dai Ren
Original Assignee
Wackvom Ltd
Kin-Ping Wong
Ming-Chung Wong
Dai Ren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wackvom Ltd, Kin-Ping Wong, Ming-Chung Wong, Dai Ren filed Critical Wackvom Ltd
Priority to EP03767196A priority Critical patent/EP1545493A4/en
Priority to AU2003263988A priority patent/AU2003263988A1/en
Priority to JP2004526444A priority patent/JP2006508047A/en
Publication of WO2004012677A2 publication Critical patent/WO2004012677A2/en
Publication of WO2004012677A3 publication Critical patent/WO2004012677A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a method to inhibit neovascularization in tissue by delivering to the cell or tissue an effective amount of sulforaphane, or a pharmaceutically acceptable salt, derivative or prodrug thereof. Also provided herein is a method for treating a disease associated with hyperproliferation of endothelial cells and/or neovascularization by administering to a subject an effective amount of sulforaphane, or a pharmaceutically acceptable salt, derivative or prodrug thereof. Kits to treat patients are provided as well.
PCT/US2003/024455 2002-08-05 2003-08-05 Methods and compositions to treat conditions associated with neovascularization WO2004012677A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03767196A EP1545493A4 (en) 2002-08-05 2003-08-05 Methods and compositions to treat conditions associated with neovascularization
AU2003263988A AU2003263988A1 (en) 2002-08-05 2003-08-05 Methods and compositions to treat conditions associated with neovascularization
JP2004526444A JP2006508047A (en) 2002-08-05 2003-08-05 Methods and formulations for treating conditions associated with neovascularization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40113002P 2002-08-05 2002-08-05
US60/401,130 2002-08-05

Publications (2)

Publication Number Publication Date
WO2004012677A2 WO2004012677A2 (en) 2004-02-12
WO2004012677A3 true WO2004012677A3 (en) 2005-02-24

Family

ID=31495928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024455 WO2004012677A2 (en) 2002-08-05 2003-08-05 Methods and compositions to treat conditions associated with neovascularization

Country Status (6)

Country Link
EP (1) EP1545493A4 (en)
JP (1) JP2006508047A (en)
CN (1) CN1723017A (en)
AU (1) AU2003263988A1 (en)
TW (1) TW200407119A (en)
WO (1) WO2004012677A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE357932T1 (en) * 2003-12-22 2007-04-15 Alcon Inc AGENTS FOR THE TREATMENT OF GLAUCOMATOUS RETINOPATHY AND OPTICAL NEUROPATHY
MX2007013396A (en) * 2005-04-29 2008-03-14 John Hokins University Methods of supressing uv light-induced skin carcinogenesis.
WO2007130353A2 (en) * 2006-05-01 2007-11-15 Johns Hopkins University Phase 2 inducers, ppar-alpha agonists and related signalling pathways protect cartilage against inflammation, apoptosis and stress
WO2009051739A1 (en) * 2007-10-16 2009-04-23 Johns Hopkins University Methods for protecting the skin from radiation insults
GB0811992D0 (en) * 2008-07-01 2008-08-06 Mithen Richard Treatment
AU2015287947B2 (en) * 2014-07-09 2017-11-23 Darlene E. MCCORD Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36784E (en) * 1993-03-12 2000-07-18 The Johns Hopkins University Chemoprotective isothiocyanates
US6433011B1 (en) * 2000-03-08 2002-08-13 American Health Foundation Method for inhibiting formation of aberrant crypt foci in the colon of a mammal

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2346325A (en) 1999-02-02 2000-08-09 Wassen Int Ltd Formulation comprising a brassica extract or sulforaphane and resveratrol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36784E (en) * 1993-03-12 2000-07-18 The Johns Hopkins University Chemoprotective isothiocyanates
US6433011B1 (en) * 2000-03-08 2002-08-13 American Health Foundation Method for inhibiting formation of aberrant crypt foci in the colon of a mammal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1545493A4 *

Also Published As

Publication number Publication date
EP1545493A2 (en) 2005-06-29
AU2003263988A8 (en) 2004-02-23
CN1723017A (en) 2006-01-18
WO2004012677A2 (en) 2004-02-12
AU2003263988A1 (en) 2004-02-23
JP2006508047A (en) 2006-03-09
EP1545493A4 (en) 2006-01-11
TW200407119A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
WO2002047673A3 (en) Methods and compositions to treat conditions associated with neovascularization
WO2009129437A3 (en) Methods and compositions for treating post-operative pain comprising clonidine
WO2007089611A3 (en) Compositions and their uses directed to huntingtin
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2006018182A8 (en) Combinations for the treatment of diseases involving cell proliferation
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
PT1933833E (en) Therapy for the treatment of overactive bladder
MXPA05010185A (en) Methods for treating or preventing an inflammatory or metabolic condition by inhibiting jnk.
NO20050851L (en) Caspase Inhibitors and Uses thereof
MXPA06012500A (en) Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production.
TW200602035A (en) [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
CY1109191T1 (en) A NEW USE OF DIFFERIPRON
NO20024646L (en) Combination therapies with vasculature-damaging activity
WO2003072030A3 (en) Methods for preventing or treating cardiac arrhythmia
MXPA05011432A (en) Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors.
WO2006031706A3 (en) Betulinol derivatives as anti-hiv agents
WO2008077062A3 (en) Suppression of stat3 reactivation after src kinase inhibition to treat cancer
WO2004012677A3 (en) Methods and compositions to treat conditions associated with neovascularization
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
WO2011022633A3 (en) Method of threating cancer
TW200515914A (en) Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same
WO2007120930A3 (en) Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
WO2004043345A3 (en) Extract of trapa natans and methods of using the same
WO2004045380A3 (en) Compositions containing an active fraction isolated from tannins and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004526444

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003767196

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038237474

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003767196

Country of ref document: EP